Stanford University
Showing 2,501-2,520 of 7,810 Results
-
Nathanael S. Gray
Krishnan-Shah Family Professor
BioNathanael Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance.
Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. During his six year stay at GNF, Dr. Gray became the director of biological chemistry where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs. Some of the notable accomplishments of Dr. Gray’s team at GNF include: discovery of the first allosteric inhibitors of wild-type and mutant forms of BCR-ABL which resulted in clinical development of ABL001; discovery of the first selective inhibitors of the Anaplastic Lymphoma Kinase (ALK), an achievement that led to the development of now FDA-approved drugs such as ceritinib (LDK378) for the treatment of EML4-ALK expressing non-small cell lung cancer (NSCLC); and discovery that sphingosine-1-phosphate receptor-1 (S1P1) is the pharmacologically relevant target of the immunosuppressant drug Fingomilod (FTY720) followed by the development of Siponimod (BAF312), which is currently used for the treatment of multiple sclerosis.
In 2006, Dr. Gray returned to academia as a faculty member at the Dana Farber Cancer Institute and Harvard Medical School in Boston. There, he has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Dr. Gray’s team developed covalent inhibitors of the T790M mutant of EGFR inspired the development of Osimertinib (AZD9291), now FDA approved for treatment of patients with relapsed lung cancer due to resistance to first generation EGFR inhibitors. Dr. Gray has also developed structure-based, generalized approaches for designing drugs to overcome one of the most common mechanisms of resistance observed against most kinase inhibitor drugs, mutation of the so-called "gatekeeper" residue, which has been observed in resistance to drugs targeting BCR-ABL, c-KIT and PDGFR.
In 2021, Dr. Gray joined Stanford University where he has joined the Stanford Cancer Institute, Chem-H and the Innovative Medicines Accelerator (IMA) to spur the development of prototype drugs.
These contributions have been recognized through numerous awards including the National Science Foundation’s Career award in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011, and the Nancy Lurie Marks endowed professorship in 2015 and the Paul Marks Prize in 2019, and the Hope Funds for Cancer Research in 2023. -
Robert M Gray
Alcatel-Lucent Professor in Communications and Networking, Emeritus
Current Research and Scholarly InterestsMy current research falls in the intersection of Shannon information theory and signal processing. In particular, I am interested in the theory and design of block codes and sliding-block (or stationary or time-invariant) codes for data compression and their relation to each other. Block codes are far better understood and more widely used, but their lack of stationarity causes difficulties in theory and artifacts in practice. Very little is known about the design of good sliding-block codes, but the problem is known to be equivalent to the design of entropy-constrained simulators of complex random processes. I also do research in the history of information theory and signal processing, especially in the development of speech processing systems and real time signal processing.
-
Carlos Greaves
Adjunct Clinical Associate Professor, Psychiatry and Behavioral Sciences
BioBorn and raised in Caracas, Venezuela. Medical school at the Central University School of Medicine, where Internship was completed.
Residency training at Stanford Medical School, Department of Psychiatry. Work in Community Mental health in Maui, Hawaii for 4 years.
Work at the Veterans Administration in Palo Alto for 3 years. Currently in Private Practice and as consulting psychiatrist at the Vaden Student Health center at Stanford -
Henry T. (Hank) Greely
Deane F. and Kate Edelman Johnson Professor of Law and, Professor, by courtesy, of Genetics
Current Research and Scholarly InterestsSince 1992 my work has concentrated on ethical, legal, and social issues in the biosciences. I am particularly active on issues arising from neuroscience, human genetics, and stem cell research, with cross-cutting interests in human research protections, human biological enhancement, and the future of human reproduction.
-
Brian Green
Physical Science Research Scientist
Current Research and Scholarly InterestsMy current research is on the dynamics and circulation of the stratosphere, focusing on quantifying the sources and effects of gravity waves. More broadly, I'm interested in and curious about a large range of topics relating to tropical climate, clouds, and the general circulation of the atmosphere and ocean.
-
Sherril L. Green, DVM, PhD
Professor of Comparative Medicine, Emerita
Current Research and Scholarly InterestsResearch Interests: Xenopus laevis. Husbandry, biology, infectious and parasitic diseases of laboratory Xenopus laevis. Large animal models of disease.
-
Tamar Green
Associate Professor of Psychiatry and Behavioral Sciences (Interdisciplinary Brain Sciences) and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsThe Brain Imaging, Development, and Genetic (BRIDGE) Lab focuses on disorders associated with child development, such as attention deficits, hyperactivity, and autism spectrum disorders. we aim to uncover biological principles of how genetic variation and its associated downstream pathways affect children's neurodevelopmental disorders.
-
Yoel Green, MD
Clinical Assistant Professor, Psychiatry and Behavioral Sciences - Sleep Medicine
BioDr. Yoel Green is a board-certified, fellowship-trained sleep medicine specialist at Stanford Health Care. He also serves as a clinical assistant professor in the Department of Psychiatry and Behavioral Sciences, Division of Sleep Medicine at Stanford University School of Medicine.
Dr. Green specializes in the diagnosis and treatment of sleep disorders, including narcolepsy, parasomnias, and obstructive sleep apnea (OSA). He also diagnoses and treats sleep-wake cycle disorders and restless legs syndrome (RLS). He integrates sleep data with patients’ lived experience to provide clear, personalized care.
Dr. Green’s research focuses on improving the diagnosis and treatment of sleep disorders. His work has appeared in peer-reviewed journals such as Biological Psychiatry and SLEEP. He has authored textbook chapters and presented at national meetings, including the American Psychiatric Association (APA) Annual Meeting.
Dr. Green is a member of the American Academy of Sleep Medicine, the APA, and the Canadian Sleep Society. -
Benjamin Daniel Greenberg
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
BioDr. Greenberg provides direct psychological care to patients in the ADAPT (Adult Depression and Anxiety Psychological Treatment) & Dual Diagnosis clinics. He is passionate about delivering evidence-based psychotherapies that are responsive and personal. He conducts individual as well as group therapy.
He teaches a psychotherapy didactic to the Addiction Medicine fellows as well as provides clinical supervision to post-doctoral fellows, doctoral students, and psychiatry residents. He is committed to helping trainees learn & work through complex situations that arise in individual & group psychotherapy. -
Harry B Greenberg
Joseph D. Grant Professor in the School of Medicine, Emeritus
Current Research and Scholarly InterestsMolecular mechanisms of pathogenesis; determinants of protective immunity; host range and tissue tropism in liver and GI tract pathogenic viruses and studies of vaccines in people.
-
Peter Greenberg
Professor of Medicine (Hematology), Emeritus
Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.
-
Maxwell Greene, MD
Clinical Associate Professor, Adult Neurology
BioDr. Greene is a board-certified, fellowship-trained neurologist. He is also a Clinical Assistant Professor of Neurology at Stanford University School of Medicine.
Dr. Greene provides clinical care for adult patients with disorders of the muscles and peripheral nerves that cause weakness and numbness. He specializes in diagnosing and treating neuromuscular diseases that include amyotrophic lateral sclerosis (ALS), all types of muscular dystrophy, chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, and Charcot-Marie-Tooth (CMT). For CIDP and CMT, Stanford is one of the few centers of excellence in the country.
A significant part of Dr. Greene’s practice involves investigational work, where he seeks to determine the cause of a patient’s symptoms. In addition to performing the full range of diagnostic tests including interpreting biopsy procedures, he has special qualifications in electrodiagnosis and the use of electromyography and nerve conduction studies.
Treatments offered by Dr. Greene cover the complete spectrum of options, with an emphasis on immune therapies for certain conditions. For CIDP and myasthenia gravis, he administers immune globulin, steroids, plasmapheresis, and rituximab. To help manage symptoms of CMT and support areas of the body weakened by this disease, he can recommend physical therapy, occupational therapy, and foot, ankle, and knee orthotics.
For the treatment of ALS and muscular dystrophy, Dr. Greene leads a multidisciplinary team offering physical and occupational therapy, pulmonary expertise, speech and swallow expertise, nutrition counseling, social services, and specialized nursing, and works together with genetic counseling. All team members collaborate closely to ensure patients receive the care and comfort needed to meet their emotional as well as physical needs.
As part of his commitment to advancing patients’ treatment options, Dr. Greene conducts clinical research. Among his current interests are
innovative new therapies for ALS and other nerve and muscular disorders. This is an exciting time in the field of neuromuscular medicine, with real potential for treatment breakthroughs for the first time in decades. Exploring these new directions enables Dr. Greene to offer Stanford patients access to options that may not be available anywhere else.
To highlight new advances for his peers, Dr. Greene has made national and regional presentations at conferences including the American Academy of Neurology meeting. Topics include the results of a study supported in part by the National Institutes of Health: paraneoplastic antibodies as markers of Hodgkin’s disease. JAMA Neurology published Dr. Greene’s article on this research.
Dr. Greene’s achievements have earned recognition from the American Academy of Neurology and other organizations. He is also the recipient of a travel award from the American Neurological Association and a grant from the NIH National Institute of Neurological Disorders and Stroke.
A member of the American Academy of Neurology, Dr. Greene is also an active member of the Western ALS Consortium and Northeastern ALS Consortium. -
Roland Greene
Director, Stanford Humanities Center, Mark Pigott KBE Professor, Anthony P. Meier Family Professor of the Humanities and Professor of Comparative Literature and, by courtesy, of Iberian and Latin American Cultures
BioRoland Greene's research and teaching are concerned with the early modern literatures of England, Latin Europe, and the transatlantic world, and with poetry and poetics from the Renaissance to the present.
His most recent book is Five Words: Critical Semantics in the Age of Shakespeare and Cervantes (Chicago, 2013). Five Words proposes an understanding of early modern culture through the changes embodied in five words or concepts over the sixteenth century: in English, blood, invention, language, resistance, and world, and their counterparts in French, Italian, Spanish, and Portuguese.
Other books include Unrequited Conquests: Love and Empire in the Colonial Americas (Chicago, 1999), which follows the love poetry of the Renaissance into fresh political and colonial contexts in the New World; and Post-Petrarchism: Origins and Innovations of the Western Lyric Sequence (Princeton, 1991), a transhistorical and comparative study of lyric poetics through the fortunes of the lyric sequence from Petrarch to Neruda. Greene is the editor with Elizabeth Fowler of The Project of Prose in Early Modern Europe and the New World (Cambridge, 1997). His essays address topics such as the colonial baroque, Edmund Spenser's Faerie Queene and Amoretti, Sir Thomas Wyatt's poetry, and Shakespeare's The Tempest.
Greene is editor in chief of the fourth edition of the Princeton Encyclopedia of Poetry and Poetics, which was published in 2012. Prepared in collaboration with the general editor Stephen Cushman and the associate editors Clare Cavanagh, Jahan Ramazani, and Paul Rouzer, this edition represents a complete revision of the most authoritative reference book on poetry and poetics.
In 2015-16 he served as President of the Modern Language Association.
At Stanford Greene has been co-chair and founder of two research workshops in which most of his Ph.D. students participate. Renaissances brings together early modernists from the Bay Area to discuss work in progress, while the Poetics Workshop provides a venue for innovative scholarship in the broad field of international and historical poetics.
Greene has taught at Harvard and Oregon, where for six years he was chair of the Department of Comparative Literature. He has held fellowships from the American Council of Learned Societies, the National Endowment for the Humanities, and the Danforth Foundation, among others. He is a member of the American Academy of Arts and Sciences.
